Pub Date : 2019-07-31DOI: 10.29328/JOURNAL.JNND.1001023
M. Luisetto, Behzad Nili Ahmadabadi, Ahmed Yesvi Rafa, R. Sahu, L. Cabianca, G. Mashori, F. Khan
Aim of this work is to produce a general theory related an new depurative strategy to be devalued for reduce or delay some spinal cord and brain degenerative and infl ammatory chronic disease or acute traumatic condition. It is used and informatics approach in order to set correct the problem and the process. Scope of this project is to submit to the researcher a new therapeutic strategy (under a depurativetoxicological-pharmacological) in this complex kind of disease. A Turing machine theory say us a method to TRASLATE the need of a strategy in a practical hypotesys of work. A global conceptual map can help in this fi eld. More Information *Address for Correspondence: Mauro Luisetto, Applied Pharmacologist, European Specialist Lab, Medicine, Branch General Toxicology, Italy; Email: maurolu65@gmail.com Submitted: 22 July 2019 Approved: 30 July 2019 Published: 31 July 2019 How to cite this article: Luisetto M, Ahmadabadi BN, Rafa AY, Sahu RK, Cabianca L, et al. The turing machine theory for some spinal cord and brain condition, A toxicological antidotic depurative approach. J Neurosci Neurol Disord.
本研究的目的是为减轻或延缓某些脊髓和大脑退行性和炎症性慢性疾病或急性创伤性疾病提供一种新的贬值策略。运用信息学的方法来设定和纠正问题和过程。该项目的范围是向研究人员提交一种新的治疗策略(在净化毒理学-药理学下)，以治疗这种复杂的疾病。图灵机理论为我们提供了一种在实际工作假设中翻译策略需求的方法。全球概念图可以在这个领域提供帮助。更多信息*通信地址:Mauro Luisetto，应用药理学家，欧洲专家实验室，医学，一般毒理学分部，意大利;Email: maurolu65@gmail.com提交时间:2019年7月22日批准时间:2019年7月30日发布时间:2019年7月31日文章来源:Luisetto M, Ahmadabadi BN, Rafa AY, Sahu RK, Cabianca L, et al.等。图灵机理论对于一些脊髓和脑部疾病，是一种毒理学解毒净化的方法。神经科学[J]。
{"title":"The turing machine theory for some spinal cord and brain condition, A toxicological - antidotic depurative approach","authors":"M. Luisetto, Behzad Nili Ahmadabadi, Ahmed Yesvi Rafa, R. Sahu, L. Cabianca, G. Mashori, F. Khan","doi":"10.29328/JOURNAL.JNND.1001023","DOIUrl":"https://doi.org/10.29328/JOURNAL.JNND.1001023","url":null,"abstract":"Aim of this work is to produce a general theory related an new depurative strategy to be devalued for reduce or delay some spinal cord and brain degenerative and infl ammatory chronic disease or acute traumatic condition. It is used and informatics approach in order to set correct the problem and the process. Scope of this project is to submit to the researcher a new therapeutic strategy (under a depurativetoxicological-pharmacological) in this complex kind of disease. A Turing machine theory say us a method to TRASLATE the need of a strategy in a practical hypotesys of work. A global conceptual map can help in this fi eld. More Information *Address for Correspondence: Mauro Luisetto, Applied Pharmacologist, European Specialist Lab, Medicine, Branch General Toxicology, Italy; Email: maurolu65@gmail.com Submitted: 22 July 2019 Approved: 30 July 2019 Published: 31 July 2019 How to cite this article: Luisetto M, Ahmadabadi BN, Rafa AY, Sahu RK, Cabianca L, et al. The turing machine theory for some spinal cord and brain condition, A toxicological antidotic depurative approach. J Neurosci Neurol Disord.","PeriodicalId":382788,"journal":{"name":"Journal of Neuroscience and Neurological Disorders","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132036189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-07-24DOI: 10.29328/JOURNAL.JNND.1001022
Аnna P Bogachuk, Z. Storozheva, A. Proshin, V. V. Sherstnev, Irina V. Smirnova, T. Shuvaeva, V. Lipkin
Cerebrovascular diseases are among the most urgent medical and social problems of the modern world. The prevalence of nervous system diseases associated with circulatory insuf iciency is up to 20% of the population and is trending upwards. Many nervous system diseases are characterized by a lingering severe course and persistent functional defects resulting in limited or total disability [1]. One of the most severe cerebrovascular diseases is ischaemic stroke (IS). Mechanisms of brain tissue damage development under conditions of cerebral ischaemia necessitate the introduction of a special type of therapy known as neuroprotection. Neuroprotection is aimed at interrupting the delayed mechanisms of cell death—oxidative stress, cytokine imbalance, local in lammation, trophic dysfunction, and apoptosis. A tight interconnection between all mechanisms of nervous tissue death motivates exploitation of the modulating effect that could be achieved through stimulation of the regulatory systems. Peptides are among the key players in regulatory processes [2]. An optimal scenario of therapy for IS and other cerebral disorders should comprise the application of agents simultaneously affecting several key components in the pathogenesis of the disease. Another important requirement for these compounds is the absence of toxic effects when used for prolonged preventive treatment. Due to Abstract
{"title":"Comparative study of carboxylate and amide forms of HLDF-6 peptide: Neuroprotective and nootropic effects in animal models of ischemic stroke","authors":"Аnna P Bogachuk, Z. Storozheva, A. Proshin, V. V. Sherstnev, Irina V. Smirnova, T. Shuvaeva, V. Lipkin","doi":"10.29328/JOURNAL.JNND.1001022","DOIUrl":"https://doi.org/10.29328/JOURNAL.JNND.1001022","url":null,"abstract":"Cerebrovascular diseases are among the most urgent medical and social problems of the modern world. The prevalence of nervous system diseases associated with circulatory insuf iciency is up to 20% of the population and is trending upwards. Many nervous system diseases are characterized by a lingering severe course and persistent functional defects resulting in limited or total disability [1]. One of the most severe cerebrovascular diseases is ischaemic stroke (IS). Mechanisms of brain tissue damage development under conditions of cerebral ischaemia necessitate the introduction of a special type of therapy known as neuroprotection. Neuroprotection is aimed at interrupting the delayed mechanisms of cell death—oxidative stress, cytokine imbalance, local in lammation, trophic dysfunction, and apoptosis. A tight interconnection between all mechanisms of nervous tissue death motivates exploitation of the modulating effect that could be achieved through stimulation of the regulatory systems. Peptides are among the key players in regulatory processes [2]. An optimal scenario of therapy for IS and other cerebral disorders should comprise the application of agents simultaneously affecting several key components in the pathogenesis of the disease. Another important requirement for these compounds is the absence of toxic effects when used for prolonged preventive treatment. Due to Abstract","PeriodicalId":382788,"journal":{"name":"Journal of Neuroscience and Neurological Disorders","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127987125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-07-18DOI: 10.29328/JOURNAL.JNND.1001021
J. Heemskerk, Oluwaseun O. Akinduro, W. Clifton, Alfredo Quiñones-Hinojosa, K. Abode-Iyamah
Introduction: Minimally invasive surgical transforaminal lumbar interbody fusion (MIS-TLIF) is a relatively new approach for fusion of the lumbar spine. It was developed in addition to traditional open transforaminal interbody fusion (OTLIF) to minimize iatrogenic soft tissue damage and prevent denervation and atrophy of the paraspinal trunk musculature. Potential disadvantages of MIS-TLIF are inadequate neural element decompression and higher risk of cage migration, resulting in persistent symptoms and a need for reoperation. Other disadvantages include inadequate visualization of bony landmarks for instrumentation, and less robust postero-lateral arthrodesis than open approaches, which may affect fusion rates. Several studies have reviewed the differences between both treatments for degenerative lumbar disease, but they mainly focused on the perioperative and short-term post-operative outcomes. Since the potential disadvantages of MIS may be expected after a longer follow-up, we performed a meta-analysis comparing MISTLIF with O-TLIF for long-term outcomes.
{"title":"Long-term clinical outcome of minimally invasive versus open single-level transforaminal lumbar interbody fusion for degenerative lumbar diseases with a minimum follow-up of 2 years: A meta-analysis protocol","authors":"J. Heemskerk, Oluwaseun O. Akinduro, W. Clifton, Alfredo Quiñones-Hinojosa, K. Abode-Iyamah","doi":"10.29328/JOURNAL.JNND.1001021","DOIUrl":"https://doi.org/10.29328/JOURNAL.JNND.1001021","url":null,"abstract":"Introduction: Minimally invasive surgical transforaminal lumbar interbody fusion (MIS-TLIF) is a relatively new approach for fusion of the lumbar spine. It was developed in addition to traditional open transforaminal interbody fusion (OTLIF) to minimize iatrogenic soft tissue damage and prevent denervation and atrophy of the paraspinal trunk musculature. Potential disadvantages of MIS-TLIF are inadequate neural element decompression and higher risk of cage migration, resulting in persistent symptoms and a need for reoperation. Other disadvantages include inadequate visualization of bony landmarks for instrumentation, and less robust postero-lateral arthrodesis than open approaches, which may affect fusion rates. Several studies have reviewed the differences between both treatments for degenerative lumbar disease, but they mainly focused on the perioperative and short-term post-operative outcomes. Since the potential disadvantages of MIS may be expected after a longer follow-up, we performed a meta-analysis comparing MISTLIF with O-TLIF for long-term outcomes.","PeriodicalId":382788,"journal":{"name":"Journal of Neuroscience and Neurological Disorders","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125944772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-07-09DOI: 10.29328/JOURNAL.JNND.1001020
Long Ching, M. Yuen, T. Poon, F. Cheung, S. Ting, W. Fong
{"title":"Mimicking multiple sclerosis - Ghost tumor that comes and goes in different parts of the brain without any treatment","authors":"Long Ching, M. Yuen, T. Poon, F. Cheung, S. Ting, W. Fong","doi":"10.29328/JOURNAL.JNND.1001020","DOIUrl":"https://doi.org/10.29328/JOURNAL.JNND.1001020","url":null,"abstract":"","PeriodicalId":382788,"journal":{"name":"Journal of Neuroscience and Neurological Disorders","volume":"88 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133672778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-03-04DOI: 10.29328/JOURNAL.JNND.1001019
M. Luisetto, N. Almukhtar, Ahmed Yesvi Rafa, Behzad Nili Ahmadabadi, G. Mashori, F. Khan, R. Sahu, Gamal Abdul Hamid, K. Edbey
Mauro Luisetto1*, Naseer Almukhtar2, Ahmed Yesvi Rafa3, Behzad Nili Ahmadabadi4, Ghulam Rasool Mashori5, Farhan Ahmad Khan6, Ram Kumar Sahu7, Gamal Abdul Hamid8 and Khaled Edbey9 1Applied Pharmacologist, Independent Researcher, Italy 2Professor, Physiology, College of Medicine, University of Babylon, Hilla, Iraq 3Founder and President, Yugen Research Organization (YRO), Independent Researcher, Bangladesh 4Pharm D/PhD Innovative Pharmaceutical Product Development Specialist, USA 5Professor of Pharmacology, People University of Medical & Health Sciences for Women, Nawabshah, Pakistan 6Associate Professor and Head, Department of Pharmacology, Government Medical College, Shahdol, M.P, India 7Associate Professor, Pt Deendayal Upadhyay Memorial Health Science and Ayush University of Chhattisgarh, Raipur, India 8Professor, Hematology Oncology, University of Aden, Aden, Yemen 9Professor, Department of Chemistry, University of Benghazi, Libya
Mauro Luisetto1*， Naseer Almukhtar2, Ahmed Yesvi raf3, Behzad Nili Ahmadabadi4, Ghulam Rasool Mashori5, Farhan Ahmad Khan6, Ram Kumar Sahu7, Gamal Abdul Hamid8和Khaled Edbey9 1意大利应用药理学家，独立研究员2伊拉克Hilla巴比伦大学医学院生理学教授3 Yugen研究组织(YRO)创始人兼总裁，孟加拉国药学博士，创新药物产品开发专家美国5巴基斯坦纳瓦布沙阿人民妇女医学与健康科学大学药理学教授6印度沙赫尔政府医学院药理学副教授兼系主任7印度莱普尔市Deendayal Upadhyay纪念健康科学博士和恰蒂斯加尔邦阿尤什大学副教授8也门亚丁大学血液肿瘤学教授9利比亚班加西大学化学系教授
{"title":"Role of plants, environmental toxins and physical neurotoxicological factors in Amyotrophic lateral sclerosis, Alzheimer Disease and other Neurodegenerative Diseases","authors":"M. Luisetto, N. Almukhtar, Ahmed Yesvi Rafa, Behzad Nili Ahmadabadi, G. Mashori, F. Khan, R. Sahu, Gamal Abdul Hamid, K. Edbey","doi":"10.29328/JOURNAL.JNND.1001019","DOIUrl":"https://doi.org/10.29328/JOURNAL.JNND.1001019","url":null,"abstract":"Mauro Luisetto1*, Naseer Almukhtar2, Ahmed Yesvi Rafa3, Behzad Nili Ahmadabadi4, Ghulam Rasool Mashori5, Farhan Ahmad Khan6, Ram Kumar Sahu7, Gamal Abdul Hamid8 and Khaled Edbey9 1Applied Pharmacologist, Independent Researcher, Italy 2Professor, Physiology, College of Medicine, University of Babylon, Hilla, Iraq 3Founder and President, Yugen Research Organization (YRO), Independent Researcher, Bangladesh 4Pharm D/PhD Innovative Pharmaceutical Product Development Specialist, USA 5Professor of Pharmacology, People University of Medical & Health Sciences for Women, Nawabshah, Pakistan 6Associate Professor and Head, Department of Pharmacology, Government Medical College, Shahdol, M.P, India 7Associate Professor, Pt Deendayal Upadhyay Memorial Health Science and Ayush University of Chhattisgarh, Raipur, India 8Professor, Hematology Oncology, University of Aden, Aden, Yemen 9Professor, Department of Chemistry, University of Benghazi, Libya","PeriodicalId":382788,"journal":{"name":"Journal of Neuroscience and Neurological Disorders","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125684783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-27DOI: 10.29328/journal.jnnd.1001017
L. M
{"title":"Endogenous archeological sciences: Physiology, Neuroscience, Biochemistry, Immunology, Pharmacology, Oncology and Genetics as instrument for a new field of investigation? Modern global aspects for a new discipline","authors":"L. M","doi":"10.29328/journal.jnnd.1001017","DOIUrl":"https://doi.org/10.29328/journal.jnnd.1001017","url":null,"abstract":"","PeriodicalId":382788,"journal":{"name":"Journal of Neuroscience and Neurological Disorders","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130909372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-10-05DOI: 10.29328/journal.jnnd.1001014
P. Jes
{"title":"Vigour of CRISPR/Cas9 Gene Editing in Alzheimer’s Disease","authors":"P. Jes","doi":"10.29328/journal.jnnd.1001014","DOIUrl":"https://doi.org/10.29328/journal.jnnd.1001014","url":null,"abstract":"","PeriodicalId":382788,"journal":{"name":"Journal of Neuroscience and Neurological Disorders","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127972031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：